EyePoint (EYPT) Stock News

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 2025 financial results and significant progress in its DURAVYU™ development program for wet AMD. The company successfully completed enrollment for two Phase 3 trials: LUGANO (432 U.S. patients) and LUCIA (over 400 global patients), both achieving unprecedented seven-month enrollment periods.

Q2 2025 financial results showed revenue of $5.3 million, down from $9.5 million in Q2 2024. The company reported a net loss of $59.4 million ($0.85 per share). EyePoint maintains a strong financial position with $256 million in cash, providing runway into 2027, beyond the expected Phase 3 topline data readouts in mid-2026.

The company's Northbridge, MA manufacturing facility is now operational and producing DURAVYU registration batches in preparation for potential FDA approval.

EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, has scheduled its second quarter 2025 financial results conference call and webcast for August 6, 2025, at 8:30 a.m. ET.

During the call, management will discuss Q2 2025 financial performance and provide updates on recent corporate developments. Investors can access the live conference call through registration and join the webcast through the company's investor relations website.

EyePoint Pharmaceuticals (Nasdaq: EYPT) has completed enrollment for its pivotal Phase 3 program testing DURAVYU™ for wet age-related macular degeneration (wet AMD). The program consists of two trials: LUCIA and LUGANO, collectively enrolling over 800 patients, making it one of the fastest-enrolling Phase 3 programs in wet AMD history.

The trials evaluate DURAVYU's 6-month redosing schedule against aflibercept, with topline data expected in mid-2026. The Data Safety Monitoring Committee has confirmed DURAVYU's safety profile, consistent with previous trials showing no related serious adverse events in over 190 patients. The Phase 3 program, developed with FDA and EMA alignment, aims to bring the first sustained-release TKI treatment for wet AMD to market.

EyePoint Pharmaceuticals (NASDAQ: EYPT), a retinal disease therapeutics company, announced the granting of inducement stock options to seven new employees on July 15, 2025. The awards, issued outside the company's 2023 Long-Term Incentive Plan, total 63,900 shares with an exercise price of $9.84 per share.

The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over three years, contingent on continued employment.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to three new employees as inducement awards. The grants, approved by the Compensation Committee, include options to purchase up to 12,500 shares of EyePoint common stock at an exercise price of $9.03 per share, which was the closing price on June 13, 2025. These options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over the following three years. The inducement awards were made outside the Company's 2023 Long-Term Incentive Plan in compliance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in three upcoming investor conferences in June 2025:

• Jefferies Global Healthcare Conference on June 4 at 1:25 p.m. ET
• Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 2:40 p.m. ET
• Guggenheim BioFrontier Boston Event on June 25 at 4:00 p.m. ET

The company will participate in fireside chats at each event, with live webcasts and archived replays available through EyePoint's investor relations website.

EyePoint Pharmaceuticals (EYPT) has completed enrollment in its Phase 3 LUGANO trial for DURAVYU™, a potential treatment for wet age-related macular degeneration (wet AMD). The trial enrolled over 400 patients in just seven months, marking one of the fastest enrollments for a wet AMD Phase 3 trial. The company's second pivotal trial, LUCIA, has reached 60% enrollment and is expected to complete in Q3 2025. Topline data from LUGANO is anticipated in mid-2026, with LUCIA results following in H2 2026. DURAVYU aims to be the first sustained-release tyrosine kinase inhibitor for wet AMD, offering 6-month redosing intervals. The trials will evaluate DURAVYU's efficacy against aflibercept, focusing on changes in best corrected visual acuity as the primary endpoint.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to seven new employees as inducement awards. The grants, approved by the Compensation Committee on May 15, 2025, include options to purchase up to 136,700 shares of EyePoint common stock at an exercise price of $5.72 per share. These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years. The inducement awards were granted outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing treatments for serious retinal diseases, has announced its participation in three upcoming investor conferences in May 2025:

- RBC Capital Markets Global Healthcare Conference: Fireside chat on May 20 at 10:00 a.m. ET
- Mizuho Neuro & Ophthalmology Summit: One-on-one meetings on May 21
- Stifel Virtual Ophthalmology Forum: Fireside chat on May 27 at 8:30 a.m. ET

Investors can access live webcasts and replays of the presentations through EyePoint's website investor section.